Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
No sign up fees
New England Journal of Medicine 2023 03 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial Rosenstock J, Frias J, Jastreboff AM, et al
[12] Most users notice meaningful changes within a few months when they stay adherent to their plan and work with their provider on optimization
This is especially helpful for patients who struggle with frequent snacking or binge eating
With substantial weight loss demonstrated in Phase II trials and an acceptable safety profile, retatrutide may emerge as a leading treatment option pending Phase III trial results and FDA approval, anticipated in 2026
It assisted in reducing liver fat, an important indicator for metabolic health, and alleviated symptoms such as knee pain and sleep apnea, which are typical among individuals with obesity
US$ 27.50
US$ 27.23
US$ 20.71
US$ 21.65
US$ 21.85
US$ 27.42
US$ 21.67
